BeyondSpring to present at lung cancer conference

BeyondSpring Pharmaceuticals Inc., a clinical stage biopharmaceutical company, announced Monday its lead compound, Plinabulin, will be presented in two posters at the upcoming 16th World Conference on Lung Cancer (WCLC) in Denver.

Set for Sunday through Wednesday, WCLC is hosted by the International Association for the Study of Lung Cancer.

The first poster, Abstract No. 1505, will present results of follow-up analysis of data from the Phase 2 study of Plinabulin combined with docetaxel in patients with advanced NSCLC. Abstract No. 1498 will be an update on the design of the upcoming Phase 3 clinical trial of Plinabulin.

The presentations will be made Tuesday and Wednesday.

"We are excited to present the global Phase 3 study and to update the lung cancer research community with our new observations and progress in clinical development of Plinabulin at the upcoming WCLC 2015, the world's largest meeting dedicated to lung and thoracic tumors,” Lan Huang, co-founder and CEO of BeyondSpring Pharmaceuticals, said. “We are pleased to have initiated this Phase 3 study with the first clinical site at University of California at San Diego and Dr. Bazhenova as our principal investigator. Based on its multiple mechanisms of action that target and alter the tumor microenvironment, we believe that Plinabulin has significant potential to extend the lives of NSCLC patients."